Regeneron Pharmaceuticals presently has a consensus price target of $629.24, indicating a potential upside of 33.47%. We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership. Our Accessibility Statement A high-level overview of Alexion Pharmaceuticals, Inc. (ALXN) stock. This table compares Regeneron Pharmaceuticals and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation. See what's happening in the market right now with MarketBeat's real-time news feed. We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations. This table compares Alexion Pharmaceuticals and Vertex Pharmaceuticals' revenue, earnings per share (EPS) and valuation. (AZN.L, AZN) agreed to buy Alexion Pharmaceuticals Inc. (ALXN) for $175 per share in cash and stock, valuing the … In December 2011, Alexion acquired Montreal-based Enobia Pharma Corp, the developer of asfotase alfa, a drug used to treat the genetic disorder hypophosphatasia. ALXN vs. BMRN: Which Stock Is the Better Value Option? Learn everything you need to know about successful options trading with this three-part video course. 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. (RTTNews) - British drug major AstraZeneca Plc. Leerink Partners Believes Alexion Pharmaceuticals (ALXN) Still Has Room to Grow. This table compares Gilead Sciences and Alexion Pharmaceuticals' net margins, return on equity and return on assets. The stock's $129 share price and $165 average price target give it a 27% upside. NasdaqGS - NasdaqGS Real Time Price. Something went wrong while loading Watchlist. Summary. Comparatively, 87.2% of Seagen shares are held by institutional investors. Alexion Pharmaceuticals has a consensus price target of $155.6818, indicating a potential upside of 2.70%. This is a breakdown of current ratings for Alexion Pharmaceuticals and Seagen, as provided by MarketBeat. Copyright © 2021 MarketWatch, Inc. All rights reserved. 76.4% of Gilead Sciences shares are owned by institutional investors. This table compares Biogen and Alexion Pharmaceuticals' gross revenue, earnings per share and valuation. Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Amgen currently has a consensus target price of $257.2174, indicating a potential upside of 11.66%. Intraday Data provided by FACTSET and subject to terms of use. Alexion Pharmaceuticals beats Gilead Sciences on 8 of the 15 factors compared between the two stocks. Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. 0.5% of Biogen shares are owned by company insiders. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. To see all exchange delays and terms of use please see disclaimer. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Visit a quote page and your recently viewed tickers will be displayed here. Alexion Pharmaceuticals (NASDAQ:ALXN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better stock? 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Prices shown are actual historical values and are not adjusted for either splits or dividends. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. 4.0% of Alexion Pharmaceuticals shares are held by insiders. View which stocks are hot on social media with MarketBeat's trending stocks report. Alexion is collaborating with Zealand Pharma A/S to discover and develop novel peptide therapies for up to four targets in the complement pathway. Subscriber Agreement & Terms of Use, Alexion Pharmaceuticals currently has a consensus target price of $155.6818, suggesting a potential upside of 2.70%. RTTNews . ALXN, Alexion Pharmaceuticals - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Gilead Sciences has higher revenue and earnings than Alexion Pharmaceuticals. Alexion Pharmaceuticals has a consensus price target of $155.6818, indicating a potential upside of 2.70%. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Stock Alert: Alexion Pharma Up 7% . Stock analysis for Alexion Pharmaceuticals Inc (ALXN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus, Nasdaq ETF's Worst Day Since October: Stocks That Survived, John Paulson's Top 5 Buys of the 4th Quarter, BioNano Genomics’ Next Double Won’t Come Easily, Zacks.com featured highlights include: Sanmina Corp, Canadian Solar, Celestica and Alexion Pharmaceuticals, Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates, Prothena's (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat, Ultragenyx (RARE) Q4 Loss Narrows Y/Y, Revenues Beat Estimates, Pick These 4 Low P/CF Stocks for a Value-Based Portfolio, Gilead (GILD) & Galapagos Discontinue Development of IPF Drug. Learn more. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Amgen (NASDAQ:AMGN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better business? Get Alexion Pharmaceuticals Inc (ALXN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation. You can opt out at any time. View our full suite of financial calendars and market data tables, all for free. Alexion Pharmaceuticals presently has a consensus target price of $155.6818, indicating a potential upside of 2.70%. Regeneron Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. © American Consumer News, LLC dba MarketBeat® 2010-2021. May. Historical and current end-of-day data provided by FACTSET. Seagen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Alexion Pharmaceuticals Inc. for $39 billion in cash and shares, adding a specialist in the treatment of rare diseases and immunology to its portfolio of medications for cancer and other illnesses. All quotes are in local exchange time. 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Biogen (NASDAQ:BIIB) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better investment? The Investor Relations website contains information about Alexion Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Alexion Pharmaceuticals topped Wall Street's fourth-quarter expectations Thursday, but ALXN stock tanked on mixed guidance for 2020.. X. This is a breakdown of current ratings and price targets for Gilead Sciences and Alexion Pharmaceuticals, as reported by MarketBeat.com. This table compares Gilead Sciences and Alexion Pharmaceuticals' gross revenue, earnings per share and valuation. Vertex Pharmaceuticals has a consensus target price of $293.1250, suggesting a potential upside of 36.76%. Amgen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report? Vertex Stock Fell After a Setback on a New Drug. 0.4% of Amgen shares are held by insiders. 5 Best PEG-Driven Value Stocks Amid COVID-Led Uncertainty, AstraZeneca (AZN) Q4 Earnings, Sales Top Despite COVID-19 Woes, Top Ranked Growth Stocks to Buy for February 10th. Stock split history for Alexion Pharmaceuticals since 1996. This is a breakdown of current ratings and recommmendations for Regeneron Pharmaceuticals and Alexion Pharmaceuticals, as provided by MarketBeat.com. 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations. It’s an Opportunity for Investors. Currency in USD. Receive a free world-class investing education from MarketBeat. Fundamental company data provided by Zacks Investment Research. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Regeneron Pharmaceuticals (NASDAQ:REGN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better stock? Should you be buying ALXN stock or one of its competitors? In May 2015, Alexion announced plans to purchase the Lexington firm Synageva BioPharma, a maker of rare disease treatments, in an $8.4 billion stock-and-cash deal. We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. For the best MarketWatch.com experience, please update to a modern browser. ALXN | Complete Alexion Pharmaceuticals Inc. stock news by MarketWatch. I want to retire in a college town with warm weather and lower taxes — where should I go? Privacy Notice, and Comparatively, Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Get short term trading ideas from the MarketBeat Idea Engine. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. While Alexion has four revenue-generating products, 70% of the company's sales have come from one drug, Soliris. (AZN.L, AZN) agreed to buy Alexion Pharmaceuticals Inc. (ALXN) for $175 per share in cash and stock, valuing the … View Alexion Pharmaceuticals, Inc. ALXN investment & stock information. This table compares Alexion Pharmaceuticals and Seagen's net margins, return on equity and return on assets. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Given Seagen's stronger consensus rating and higher possible upside, analysts plainly believe Seagen is more favorable than Alexion Pharmaceuticals. Alexion Pharmaceuticals stock price ended on $151.59 on Friday after gaining 0.0924% (Updated on March 12, 2021) Sell candidate since 2021-03-02 Gain 0.81% PDF . Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Alexion Pharmaceuticals, Inc. (ALXN) Add to watchlist. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Alexion Stock Jumps on Signal That Fight Over Patent May End Soon. This table compares Biogen and Alexion Pharmaceuticals' net margins, return on equity and return on assets. Learn about financial terms, types of investments, trading strategies and more. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA. Biogen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Given Amgen's stronger consensus rating and higher possible upside, equities analysts clearly believe Amgen is more favorable than Alexion Pharmaceuticals. 83.5% of Biogen shares are owned by institutional investors. Alexion Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors, Alexion Pharmaceuticals Inc. stock falls Tuesday, underperforms market, Alexion Pharmaceuticals Inc. stock falls Monday, underperforms market, AstraZeneca Sold Its Stake in Rival Covid-19 Vaccine Maker Moderna for More Than $1 Billion, Alexion Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, Alexion Pharmaceuticals Inc. stock underperforms Monday when compared to competitors, Alexion Pharmaceuticals Inc. stock rises Thursday, outperforms market, Alexion Pharmaceuticals Inc. stock rises Wednesday, outperforms market, Immunovant (IMVT) Gains on a Potential Buyout by Roivant. 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Alexion Pharmaceuticals. There are currently no items in this Watchlist. Start Your Risk-Free Trial Subscription Here, Editor of top German newspaper suspended in compliance probe, Timing key in consulting deal between FirstEnergy, regulator, You Must Recognize Your Own Achievements First Before Expecting Others To, The Latest: Paris may face new lockdown as ICUs fill up, 'Big burden' for schools trying to give kids internet access, The Latest: Pakistan imposes partial lockdown in some areas, Three Mall Retailers For Your Reopening Watchlist, 3 Growth Stocks with Above Market Dividend Yields, 3 Best Stocks to Buy That You’ve Probably Never Heard Of, Ferroglobe Will Get a Big Lift From Demand For Silcon Wafers, Blue Bird Stock is a Dual Tailwinds EV and Re-Opening Play, Nautilus Stock is a Pullback Buying Opportunity Here, The Launch of Truforma Should Send Zomedica to An All-Time High, Defi Markets Pause But New Highs Are In Sight, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, Receive Analysts' Upgrades and Downgrades Daily. Alexion stock has been a laggard in the pharma space, largely moving sideways in recent years, despite posting strong growth (sales grew at an average of 17% each year over the last 5 years). Learn more. This table compares Amgen and Alexion Pharmaceuticals' net margins, return on equity and return on assets. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by insiders. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Biogen beats Alexion Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Given Gilead Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Gilead Sciences is more favorable than Alexion Pharmaceuticals. Please log in to your account or sign up in order to add this asset to your watchlist. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Please see … This table compares Regeneron Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets. This is a breakdown of current ratings and recommmendations for Amgen and Alexion Pharmaceuticals, as reported by MarketBeat. Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Alexion Pharmaceuticals has higher revenue and earnings than Seagen. Alexion Pharmaceuticals Inc. stock rises Friday, still underperforms market, Alexion Pharmaceuticals Inc. stock falls Thursday, underperforms market, Alexion Pharmaceuticals Inc. stock rises Wednesday, still underperforms market, Alexion Pharmaceuticals Inc. stock outperforms market on strong trading day, Alexion Pharmaceuticals Inc. stock outperforms market despite losses on the day. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 All rights reserved. Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Biogen currently has a consensus price target of $304.4667, indicating a potential upside of 14.41%. Seagen beats Alexion Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. How has Alexion Pharmaceuticals's share price performed over time and what events caused price changes? Identify stocks that meet your criteria using seven unique stock screeners. Create a list of the investments you want to track. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Alexion Pharmaceuticals has a consensus target price of $155.6818, indicating a potential upside of 2.70%. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. 24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. Its products include ultomiris, soliris, strensiq and kanuma. This table compares Alexion Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets. Log in to see them here or sign up to get started. Comparatively, 31.1% of Seagen shares are held by insiders. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. The Alexion Pharmaceuticals stock price gained 0.0924% on the last trading day (Friday, 12th Mar 2021), rising from $151.45 to $151.59.During the day the stock fluctuated 1.28% from a day low at $149.87 to a day high … Amgen has higher revenue and earnings than Alexion Pharmaceuticals. Under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola’s common stock at a price of $18 per share in cash. Gilead Sciences (NASDAQ:GILD) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better investment? Find real-time ALXN - Alexion Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Alexion Pharmaceuticals has a consensus price target of $155.6818, suggesting a potential upside of 2.70%. Gilead Sciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Export data to Excel for your own analysis. 28, 2020, 09:58 AM (RTTNews) - Shares of Alexion Pharmaceuticals Inc (ALXN) are rising … Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. This table compares Alexion Pharmaceuticals and Seagen's top-line revenue, earnings per share and valuation.